Quick Takeaways
- RNAZ - Transcode Therapeutics, Inc. has 9 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are not currently available.
Insider Transactions Reported by 9 Insiders of Transcode Therapeutics, Inc.
- Symbol
- RNAZ on Nasdaq
- Location
- Boston, MA
What Changed
- No meaningful buy/sell imbalance is currently visible in the one-year window.
- Activity will update as new Forms 3/4/5 are filed.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsInsider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 30 Apr 2025.
Buys
$0
Shares: 0
Insiders: 0
Sells
$0
Shares: 0
Insiders: 0
Net
$0
Shares: 0
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Transcode Therapeutics, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Anna Moore | 10%+ Owner | $791,920 | Mixed | 08 Jul 2021 | ||
| Robert Michael Dudley | Chief Executive Officer, Director | $91,934 | Filing P/S | 28 Sep 2023 | ||
| Thomas A. Fitzgerald | Interim CEO, CFO, Director | $28,722 | Filing P/S | 14 Jun 2024 | ||
| Philippe Calais | Director | Mixed | 14 Jun 2024 | |||
| Jack E. Stover | Director | Mixed | 19 Dec 2025 | |||
| Erik Manting | Director | Mixed | 14 Jun 2024 | |||
| Elizabeth Czerepak | Director | Mixed | 06 Oct 2025 | |||
| Magda Marquet | Director | Mixed | 14 Jun 2024 | |||
| Zdravka Medarova | Chief Technology Officer, 10%+ Owner | Mixed | 12 Dec 2022 |
Top shareholders of Transcode Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| CK Life Sciences Intl (Holdings) Inc |
13D/G
|
CK Life Sciences Int'l., (Holdings) Inc. |
9.1%
|
83,285
|
$871,161 | $0 | 27 Oct 2025 | |
| Anna Moore |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,552,785
|
$791,920 | — | 08 Jul 2021 | |
| SABBY MANAGEMENT, LLC |
13D/G
|
— |
4.9%
|
41,601
|
$433,482 | $0 | 31 Dec 2025 | |
| Robert Michael Dudley |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
180,262
|
$91,934 | — | 28 Sep 2023 | |
| YA II PN, Ltd. |
13D/G
|
— |
9.9%
|
101,772
|
$35,620 | $0 | 15 Apr 2026 | |
| Thomas A. Fitzgerald |
3/4/5
|
Interim CEO, CFO, Director |
—
mixed-class rows
|
706,318
mixed-class rows
|
$28,722 | — | 14 Jun 2024 | |
| UBS Group AG |
13F
|
Company |
0.35%
|
2,964
|
$20,245 | — | 31 Dec 2025 | |
| Thomas Joseph Tracy |
13D/G
|
— |
5%
|
35,000
|
$13,300 | $0 | 07 Mar 2025 | |
| Anson Funds Management LP |
13D/G
|
— |
0.1%
|
27,125
|
$9,494 | -$30,224 | 30 Jun 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.1%
|
887
|
$6,058 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13D/G
|
THE GOLDMAN SACHS GROUP, INC. |
0.01%
|
82
|
$882 | -$526,307 | 30 Sep 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
10
|
$68 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
8
|
$55 | — | 31 Dec 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
3
|
$20 | — | 31 Dec 2025 | |
| Erik Manting |
3/4/5
|
Director |
—
class O/S missing
|
70,000
|
— | — | 14 Jun 2024 | |
| Magda Marquet |
3/4/5
|
Director |
—
class O/S missing
|
70,000
|
— | — | 14 Jun 2024 | |
| Philippe Calais |
3/4/5
|
Director |
—
class O/S missing
|
70,000
|
— | — | 14 Jun 2024 | |
| Zdravka Medarova |
3/4/5
|
Chief Technology Officer, 10%+ Owner |
—
class O/S missing
|
60,000
|
— | — | 12 Dec 2022 |
Recent Insider Transactions by Companies or Individuals for Transcode Therapeutics, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* An asterisk sign (*) next to the price indicates that the price is likely invalid.